Could Anti-Obesity Drugs Treat Binge Eating Disorder?
GLP-1 drugs may help binge eating disorder by addressing both weight and potentially the neurobiological underpinnings of compulsive eating, but evidence is still sparse.
Quick Facts
What This Study Found
Anti-obesity drugs, particularly GLP-1 receptor agonists, may have potential for treating binge eating disorder, but current evidence is limited and the psychological components of BED require special attention.
Key Numbers
BED is described as the most prevalent form of disordered eating. Only lisdexamfetamine is currently approved for BED, and only in some countries.
How They Did This
Narrative review of existing literature on anti-obesity drugs and their potential role in binge eating disorder treatment.
Why This Research Matters
Binge eating disorder is extremely common but has very few approved treatments. If obesity drugs can address both the weight and the eating behavior, it could help millions of people.
The Bigger Picture
With only one approved treatment available in limited countries, binge eating disorder is severely undertreated. If obesity drugs could address both weight and eating behavior, millions of people could benefit.
What This Study Doesn't Tell Us
This is a narrative review, not a systematic review or meta-analysis. Direct evidence for GLP-1 agonists in BED specifically is sparse.
Questions This Raises
- ?Do GLP-1 drugs reduce binge eating urges or just overall appetite?
- ?Should BED-specific clinical trials be designed for GLP-1 drugs?
Trust & Context
- Key Stat:
- Only 1 approved BED drug Lisdexamfetamine is the only approved medication for binge eating disorder, and only in some countries
- Evidence Grade:
- Rated preliminary: narrative review exploring a hypothesis with limited direct evidence. No randomized trials of GLP-1 drugs specifically for BED.
- Study Age:
- Published in 2024. Reflects growing interest in GLP-1 drugs for conditions beyond diabetes and general obesity.
- Original Title:
- Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.
- Published In:
- Alpha psychiatry, 25(3), 312-322 (2024)
- Authors:
- Riboldi, Ilaria, Carrà, Giuseppe
- Database ID:
- RPEP-09145
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can Ozempic or Wegovy help binge eating?
There are theoretical reasons to think so — GLP-1 receptors exist in brain reward circuits — but specific clinical trials for binge eating disorder haven't been done yet.
What treatments exist for binge eating disorder?
Cognitive behavioral therapy is the gold standard. Lisdexamfetamine is the only approved drug, available in limited countries. Anti-obesity drugs are being explored.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09145APA
Riboldi, Ilaria; Carrà, Giuseppe. (2024). Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.. Alpha psychiatry, 25(3), 312-322. https://doi.org/10.5152/alphapsychiatry.2024.241464
MLA
Riboldi, Ilaria, et al. "Anti-obesity Drugs for the Treatment of Binge Eating Disorder: Opportunities and Challenges.." Alpha psychiatry, 2024. https://doi.org/10.5152/alphapsychiatry.2024.241464
RethinkPeptides
RethinkPeptides Research Database. "Anti-obesity Drugs for the Treatment of Binge Eating Disorde..." RPEP-09145. Retrieved from https://rethinkpeptides.com/research/riboldi-2024-antiobesity-drugs-for-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.